Page 2 - Carm Leal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Carm leal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Carm Leal Today - Breaking & Trending Today

Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of "Buy" from Brokerages

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has been assigned an average recommendation of “Buy” from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have updated their coverage on the stock […] ....

Jump Financial , Virtu Financial , Carisma Therapeutics Inc , Blodgett Wealth Advisors , Connor Clark Lunn Investment Management Ltd , Stratos Wealth Partners , Carisma Therapeutics , Get Free Report , Marketbeat Ratings , One Financial , Wealth Advisors , Wealth Partners , Connor Clark , Lunn Investment Management , Get Free , Carisma Therapeutics Daily , Nasdaq Carm ,

Carisma Therapeutics, Inc. (NASDAQ:CARM) Sees Significant Decrease in Short Interest

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) saw a large decrease in short interest in September. As of September 15th, there was short interest totalling 2,580,000 shares, a decrease of 8.5% from the August 31st total of 2,820,000 shares. Based on an average trading volume of 234,300 shares, the short-interest ratio is currently 11.0 […] ....

Virtu Financial , Carisma Therapeutics Inc , Connor Clark Lunn Investment Management Ltd , University Of Pennsylvania , Asset Management Inc , Carisma Therapeutics Company Profile , Wittenberg Investment Management Inc , Carisma Therapeutics , Get Free Report , Therapeutics Stock Down , Investment Management , Lunn Investment Management , Management Inc , Carisma Therapeutics Daily , Nasdaq Carm ,

Carisma Therapeutics (NASDAQ:CARM) Rating Reiterated by HC Wainwright

Carisma Therapeutics (NASDAQ:CARM – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $11.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 121.33% from the stock’s previous close. Other analysts have also […] ....

United States , Barclays Plc , Jefferies Financial Group , Wells Fargo Company , Citigroup Inc , Carisma Therapeutics Inc , Manufacturers Life Insurance Company , Carisma Therapeutics , Get Free Report , Financial Group , Therapeutics Stock Down , State Teachers Retirement System , Carisma Therapeutics Daily , Nasdaq Carm , Reiterated Rating , Hc Wainwright ,

Carisma Therapeutics (NASDAQ:CARM) Price Target Increased to $11.00 by Analysts at HC Wainwright

Carisma Therapeutics (NASDAQ:CARM – Get Free Report) had its price target boosted by equities research analysts at HC Wainwright from $10.00 to $11.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 74.33% from […] ....

Robertw Baird , Capital Management , Stratos Wealth Partners , University Of Pennsylvania , Blodgett Wealth Advisors , Carisma Therapeutics Inc , Virtu Financial , Jefferies Financial Group , Carisma Therapeutics , Get Free Report , Financial Group , Wealth Partners , Wealth Advisors , Carisma Therapeutics Daily , Nasdaq Carm , Boost Price Target , Hc Wainwright ,